A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs MEDI 0382 (Primary) ; Liraglutide; Metformin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2017 Planned End Date changed from 27 Apr 2020 to 23 Mar 2020.
- 08 Sep 2017 Planned End Date changed from 29 Apr 2020 to 27 Apr 2020.